Antiphospholipid antibodies (aPL) may induce acquired activated protein C resistance (acquired APCR). The role of acquired APCR in patients with systemic lupus erythematosus (SLE) is not well known. To evaluate the prevalenceof acquiredAPCR and its associationwith clinical manifestations we studied 103 consecutive SLE patients and 103 matched controls. APCR in the undiluted test and after dilution in factor V deficient plasma, factor V Leiden, protein C and S, lupus anticoagulant,and anti-cardiolipin,anti-β2-glycoprotein I and anti-prothrombin antibodies were determined. Factor V Leiden was found in 4% in both patients and controls.The prevalenceof acquiredAPCR was 22% for the undiluted assay and 17% in the diluted test. In SLE patients,acquired APCR was associated with aPL (39 vs 13% in undiluted assay, P=0.007; and 33 vs 7% in the diluted test, P=0.001). Arterial thromboses were found in 24% of patients with acquired APCR and in 6% of patients without (P=0.04). However, no relationship was found with venous thrombosis. Acquired APCR was also associated with pregnancy losses: miscarriages in 70% of women with acquired APCR vs 32% in those without (P=0.03). Thus, in SLE patients acquired APCR seems to be associated with increased prevalence of arterial thrombosis and pregnancy losses.
Cervera R , Khamashta MA , Font J et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients . Medicine (Balt)1993; 72: 113–124 .
Tsakiris DA , Settas L , Makris PE , Marbet GA . Lupus anticoagulant— antiphospholipid antibodies and thrombophilia. Relation to protein C–protein S–Thrombomodulin . J Rheumatol1990; 17: 785–789 .
4.
Parke AL , Weinstein RE , Bona RD , Maier DB , Walker FJ . The thrombotic diathesis associated with the presence of phospholipid antibodies may be due to low levels of free protein S . Am J Med1992; 93: 49–56 .
5.
Tomas JF , Alberca I , Tabernero MD , Cordero M , Del Pino-Montes J , Vicente V . Natural anticoagulant proteins and antiphospholipid anti-bodies in systemic lupus erythematosus . J Rheumatol1998; 25: 57–62 .
6.
Malia RG , Kitchen S , Greaves M , Preston FE . Inhibition of activated protein C and its cofactor protein S by antiphospholipidantibodies . Br J Haematol1990; 76: 101–107 .
7.
Marciniak E , Romond EH . Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant . Blood1989; 74: 2426–2432 .
8.
Borrell M , Sala N , Castellarnau C , Lopez S , Gari M , Fontcuberta J . Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells . Thromb Haemost1992; 68: 268–272 .
9.
Dahlbäck B , Carlsson M , Svensson PJ . Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C . Proc Natl Acad Sci1993; 90: 1004–1008 .
10.
Svensson PJ , Dahlbäck B . Resistance to protein C as a basis for venous thrombosis . New Engl J Med1994; 330: 517–522 .
11.
Bertina RM , Koeleman BPC , Koster T et al. Mutation in blood coagulation factor V associated with resistance to activated protein C . Nature1994; 369: 64–67 .
12.
Cumming AM , Tait RC , Fildes S , Yoong A , Keeney S , Hay CRM . Development of resistance to activated protein C during pregnancy . Br J Haematol1995; 90: 725–727 .
13.
Rosing J , Middeldorp S , Curvers J et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study . Lancet1999; 354: 2036–2040 .
14.
Ruiz-Argüelles GJ . Protein C resistance and antiphospholipid anti-bodies . Lupus1996; 5: 633-633 .
15.
Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum1982; 25: 1271–1277 .
16.
Brandt JT , Barna LK , Triplett DA . Laboratory identification of lupus anticoagulants: results of The Second International Workshop for identification of lupus anticoagulants . Thromb Haemost1995; 74: 1597–1603 .
17.
Exner T , Rickard KA , Kronenberg H . A sensitive test demonstrating lupus anticoagulant and its behavioural patterns . Br J Haematol1978; 40: 143–151 .
18.
Thiagarajan P , Pengo V , Shapiro SS . The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants . Blood1986; 68: 869–874 .
19.
Galli M , Finazzi G , Bevers EM , Barbui T . Kaolin Clotting Time and dilute Russell's viper venom time distinguish between prothrombinand beta 2-glycoprotein I-dependent antiphospholipid antibodies . Blood1995; 86: 617–623 .
20.
Gharavi AE , Harris EN , Asherson RA , Hughes GRV . Anticardiolipin antibodies: isotype distribution and phospholipid specificity . Ann Rheum Dis1987; 46: 1–6 .
21.
Muñoz-Rodríguez FJ , Reverter JC , Font J et al. Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome . Haematologica2000; 85: 632–637 .
22.
Teixidó M , Font J , Reverter JC et al. Anti-b-2-glycoprotein I anti-bodies: a useful marker for the antiphospholipid syndrome . Br J Rheumatol1997; 36: 113–116 .
23.
Thein SL , Walance RB . The use of synthetic oligonucleotides as specific hybridization probes in the diagnosis of genetic disorders. In: Davis KE (ed.), Human Genetic Diseases, a Practical Approach. IRL Press: Oxford , 1986, pp 33–50.
24.
Bengtsson A , Zöller B , de Frutos PG , Dahlbäck B , Sturfelt G . Factor V:Q506mutation and anticardiolipin antibodies in systemic lupus erythematosus . Lupus1996; 5: 598–601 .
25.
Sasso EH , Suzuki LA , Thompson AR , Petri MA . Hereditary resistance to activated protein C: an uncommon risk factor for thromboembolic disease in lupus patients with antiphospholipid antibodies . Arthritis Rheum1997; 40: 1720–1724 .
26.
Ruiz-Argüelles GJ , Garcés-Eisele J , Alarcón-Segovia D , Ruiz-Argüelles A . Activated protein C resistance phenotype and genotype in patients with primary antiphospholipid syndrome . Blood Coag Fibrinol1996; 7: 344–348 .
27.
Biousse V , Piette JC , Frances C et al. Primary antiphospholid syndrome is not associated with activated protein C resistance by factor V Arg 506?Gln mutation . J Rheumatol1995; 22: 1215-1215 (Letter).
28.
Cortese-Hassett A , Bontempo F , Faruki H et al. Activated protein C resistance (APCr) and factor V Leiden in patients with SLE . Blood1995; 86: 204a–204a (Abstract).
29.
Male C , Mitchell L , Julian J et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus . Blood2001; 97: 844–849 .
30.
Martinuzzo M , Forastiero R , Adamczuk Y , Cerrato G , Carreras O . Activated protein C resistance in patients with anti-β2 glycoprotein I antibodies . Blood Coag Fibrinol1996; 7: 702–704 .
31.
Ehrenforth S , Radtke KP , Scharrer I . Acquired activated protein C-resistance in patients with lupus anticoagulants . Thromb Haemost1995; 74: 797–798 .
32.
Tsakiris DA , Yasikoff ML , Wolf F , Marbet GA . Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro . Ann Hematol1995; 71: 195–198 .
33.
Galli M , Finazzi G , Norbis F , Marziali S , Marchioli R , Barbui T . The Risk of Thrombosis in Patients with Lupus Anticoagulants is predicted by their specific coagulation profile . Thromb Haemost1999; 81: 695–700 .
34.
Clouse LH , Comp PC . The regulation of hemostasis: the protein C system . New Engl J Med1986; 314: 1298–1304 .
35.
Key NS . Toward an understanding of the pathophysiologicmechanism of thrombosis in the antiphospholipidsyndrome . J Lab Clin Med1995; 125: 16–17 .
36.
van der Bom JG , Bots ML , Haverkate F et al. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease . Ann Intern Med1996; 125: 265–269 .
37.
Kiechl S , Muigg A , Santer P et al. Poor response to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease . Circulation1999; 99: 614–619 .
38.
Rosendaal FR , Siscovick DS , Schwartz SM et al. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women . Blood1997; 89: 2817–2821 .
39.
Doggen CJ , Cats VM , Bertina RM , Rosendaal FR . Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A . Circulation1998; 97: 1037–1041 .
40.
Inbal A , Freimark D , Modan B et al. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males . Blood1999; 93: 2186–2190 .
41.
Aznar J , Villa P , España F , Estellés A , Grancha S , Falcó C . Activated protein C resistance phenotype in patients with antiphospholipid antibodies . J Lab Clin Med1997; 130: 202–208 .
42.
Bokarewa MI , Blomback M , Bremme K . Phospholipid antibodies and resistance to activated protein C in women with thrombophilia . Blood Coag Fibrinol1995; 6: 417–422 .
43.
Galli M , Duca F , Ruggeri L , Finazzi G , Negri B , Moia M . Congenital resistance to activated protein C in patients with lupus anticoagulants: Evaluation of two functional assays . Thromb Haemost1998; 80: 246–249 .
44.
Brenner B . Inherited thrombophilia and fetal loss . Curr Opin Hematol2000; 7: 290–295 .
45.
Rai R , Shlebak A , Cohen H et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage . Hum Reprod2001; 16: 961–965 .
46.
Younis JS , Brenner B , Ohel G , Tal J , Lanir N , Ben-Ami M . Activated protein C resistance and factor V Leiden mutation can be associated with first—as well as second—trimester recurrent pregnancy loss . Am J Reprod Immunol2000; 43: 31–35 .
47.
Tal J , Schliamser LM , Leibovitz Z , Ohel G , Attias D . A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure . Hum Reprod1999; 14: 211–214 .
48.
Grandone E , Margaglione M , Colaizzo D et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses . Thromb Haemost1997; 7: 822–824 .
